Literature DB >> 31302671

High dose vitamin D exacerbates central nervous system autoimmunity by raising T-cell excitatory calcium.

Darius Häusler1, Sebastian Torke1, Evelyn Peelen2, Thomas Bertsch3, Marija Djukic1,4, Roland Nau1,4, Catherine Larochelle2, Scott S Zamvil5, Wolfgang Brück1, Martin S Weber1,6.   

Abstract

Poor vitamin D status is associated with a higher relapse rate and earlier disability in multiple sclerosis. Based on these associations, patients with multiple sclerosis are frequently supplemented with the vitamin D precursor cholecalciferol, although it is unclear whether this regimen is of therapeutic benefit. To model consequences of this common practice, mice were fed for more than 3 months with a low, medium or high dose of cholecalciferol, representative of vitamin D deficiency, modest and disproportionally high supplementation, respectively, in patients with multiple sclerosis. Compared to vitamin D-deprived mice, its moderate supplementation reduced the severity of subsequent experimental autoimmune encephalomyelitis, which was associated with an expansion of regulatory T cells. Direct exposure of murine or human T cells to vitamin D metabolites inhibited their activation. In contrast, mice with 25-(OH) vitamin D levels above 200 nmol/l developed fulminant experimental autoimmune encephalomyelitis with massive CNS infiltration of activated myeloid cells, Th1 and Th17 cells. When dissecting this unexpected outcome, we observed that high, but not medium dose vitamin D had caused mild hypercalcaemia, which rendered T cells more prone to pro-inflammatory activation. Exposing murine or human T cells to equivalent calcium concentrations in vitro enhanced its influx, triggering activation, upregulation of pro-inflammatory gene products and enhanced transmigration across a blood-brain barrier model. These findings suggest that vitamin D at moderate levels may exert a direct regulatory effect, while continuous high dose vitamin D treatment could trigger multiple sclerosis disease activity by raising mean levels of T-cell excitatory calcium.
© The Author(s) (2019). Published by Oxford University Press on behalf of the Guarantors of Brain. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  T cells; calcium; experimental autoimmune encephalomyelitis; multiple sclerosis; vitamin D

Mesh:

Substances:

Year:  2019        PMID: 31302671      PMCID: PMC6736324          DOI: 10.1093/brain/awz190

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  75 in total

Review 1.  Calcium signaling mechanisms in T lymphocytes.

Authors:  R S Lewis
Journal:  Annu Rev Immunol       Date:  2001       Impact factor: 28.527

2.  The vitamin D receptor is necessary for 1alpha,25-dihydroxyvitamin D(3) to suppress experimental autoimmune encephalomyelitis in mice.

Authors:  Terrence F Meehan; Hector F DeLuca
Journal:  Arch Biochem Biophys       Date:  2002-12-15       Impact factor: 4.013

3.  Some comments on the relationship of the distribution of multiple sclerosis to latitude, solar radiation, and other variables.

Authors:  E D ACHESON; C A BACHRACH; F M WRIGHT
Journal:  Acta Psychiatr Scand Suppl       Date:  1960

4.  Expression of 1,25-dihydroxyvitamin D(3) receptor in the immune system.

Authors:  C M Veldman; M T Cantorna; H F DeLuca
Journal:  Arch Biochem Biophys       Date:  2000-02-15       Impact factor: 4.013

Review 5.  Vitamin D supplementation, 25-hydroxyvitamin D concentrations, and safety.

Authors:  R Vieth
Journal:  Am J Clin Nutr       Date:  1999-05       Impact factor: 7.045

Review 6.  Sunlight and vitamin D for bone health and prevention of autoimmune diseases, cancers, and cardiovascular disease.

Authors:  Michael F Holick
Journal:  Am J Clin Nutr       Date:  2004-12       Impact factor: 7.045

Review 7.  Vitamin D status, 1,25-dihydroxyvitamin D3, and the immune system.

Authors:  Margherita T Cantorna; Yan Zhu; Monica Froicu; Anja Wittke
Journal:  Am J Clin Nutr       Date:  2004-12       Impact factor: 7.045

8.  1,25-dihydroxyvitamin D3 treatment decreases macrophage accumulation in the CNS of mice with experimental autoimmune encephalomyelitis.

Authors:  F E Nashold; D J Miller; C E Hayes
Journal:  J Neuroimmunol       Date:  2000-03-01       Impact factor: 3.478

9.  In vitro generation of interleukin 10-producing regulatory CD4(+) T cells is induced by immunosuppressive drugs and inhibited by T helper type 1 (Th1)- and Th2-inducing cytokines.

Authors:  Franck J Barrat; Daniel J Cua; André Boonstra; David F Richards; Chad Crain; Huub F Savelkoul; René de Waal-Malefyt; Robert L Coffman; Catherine M Hawrylowicz; Anne O'Garra
Journal:  J Exp Med       Date:  2002-03-04       Impact factor: 14.307

10.  Critical role of the programmed death-1 (PD-1) pathway in regulation of experimental autoimmune encephalomyelitis.

Authors:  Alan D Salama; Tanuja Chitnis; Jaime Imitola; Mohammed Javeed I Ansari; Hisaya Akiba; Fumihiko Tushima; Miyuki Azuma; Hideo Yagita; Mohamed H Sayegh; Samia J Khoury
Journal:  J Exp Med       Date:  2003-07-07       Impact factor: 14.307

View more
  14 in total

1.  Reply: Neither human nor mouse is hypercalcaemic with 250 nmol/l 25-hydroxyvitamin D.

Authors:  Darius Häusler; Sebastian Torke; Evelyn Peelen; Thomas Bertsch; Matthias Weber; Marcus Heilmann; Marija Djukic; Roland Nau; Catherine Larochelle; Scott S Zamvil; Wolfgang Brück; Martin S Weber
Journal:  Brain       Date:  2020-02-01       Impact factor: 13.501

2.  Reply: Hypercalcaemia rather than high dose vitamin D3 supplements could exacerbate multiple sclerosis.

Authors:  Darius Häusler; Sebastian Torke; Evelyn Peelen; Thomas Bertsch; Marija Djukic; Roland Nau; Catherine Larochelle; Scott S Zamvil; Wolfgang Brück; Martin S Weber
Journal:  Brain       Date:  2019-12-01       Impact factor: 13.501

Review 3.  Full spectrum of vitamin D immunomodulation in multiple sclerosis: mechanisms and therapeutic implications.

Authors:  Manon Galoppin; Saniya Kari; Sasha Soldati; Arindam Pal; Manon Rival; Britta Engelhardt; Anne Astier; Eric Thouvenot
Journal:  Brain Commun       Date:  2022-06-30

4.  Supplementary medication in multiple sclerosis: Real-world experience and potential interference with neurofilament light chain measurement.

Authors:  Katrin Pape; Falk Steffen; Frauke Zipp; Stefan Bittner
Journal:  Mult Scler J Exp Transl Clin       Date:  2020-08-27

Review 5.  Vitamin D as a Potential Therapy for Multiple Sclerosis: Where Are We?

Authors:  Samiksha Wasnik; Isha Sharma; David J Baylink; Xiaolei Tang
Journal:  Int J Mol Sci       Date:  2020-04-28       Impact factor: 5.923

Review 6.  A Brief Review of the Effects of Vitamin D on Multiple Sclerosis.

Authors:  Andrei Miclea; Maud Bagnoud; Andrew Chan; Robert Hoepner
Journal:  Front Immunol       Date:  2020-05-06       Impact factor: 7.561

Review 7.  High-Dose Vitamin D-Mediated Hypercalcemia as a Potential Risk Factor in Central Nervous System Demyelinating Disease.

Authors:  Darius Häusler; Sebastian Torke; Martin S Weber
Journal:  Front Immunol       Date:  2020-02-25       Impact factor: 7.561

8.  Reduced Vitamin D Levels are Associated with Stroke-Associated Pneumonia in Patients with Acute Ischemic Stroke.

Authors:  Gui-Qian Huang; Hao-Ran Cheng; Yue-Min Wu; Qian-Qian Cheng; Yu-Min Wang; Jia-Li Fu; Hui-Xin Zhou; Zhen Wang
Journal:  Clin Interv Aging       Date:  2019-12-31       Impact factor: 4.458

Review 9.  Vitamin D Supplementation in Multiple Sclerosis: A Critical Analysis of Potentials and Threats.

Authors:  Julia Feige; Tobias Moser; Lara Bieler; Kerstin Schwenker; Larissa Hauer; Johann Sellner
Journal:  Nutrients       Date:  2020-03-16       Impact factor: 5.717

10.  Glatiramer acetate immune modulates B-cell antigen presentation in treatment of MS.

Authors:  Darius Häusler; Zivar Hajiyeva; Jan W Traub; Scott S Zamvil; Patrice H Lalive; Wolfgang Brück; Martin S Weber
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2020-03-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.